Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde
E O
EO
Department of Surgery, University of Leicester, Leicester General Hospital, United Kingdom.
Wheatley
T
T
Feehally
J
J
Nicholson
M L
ML
Veitch
P S
PS
Bell
P R
PR
D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009543:Nifedipine / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors; D014019:Tissue Donors; D014481:United States
D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D009543:Nifedipine; D001379:Azathioprine